Literature DB >> 23515148

Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets.

Yeou-mei Christiana Liu1, Huei-Shyong Wang.   

Abstract

The ketogenic diet (KD) is one of the most effective therapies for drug-resistant epilepsy. The efficacy of the medium-chain triglyceride KD (MCTKD) is as excellent as the classic KD (CKD), which has been documented in several subsequent retrospective, prospective, and randomized studies. MCT oil is more ketogenic than long-chain triglycerides. Therefore, the MCTKD allows more carbohydrate and protein food, which makes the diet more palatable than the CKD. The MCTKD is not based on diet ratios as is the CKD, but uses a percentage of calories from MCT oil to create ketones. There has also been literature which documents the associated gastrointestinal side effects from the MCTKD, such as diarrhea, vomiting, bloating, and cramps. Therefore, the MCTKD has been an underutilized diet therapy for intractable epilepsy among children.The author has used up to >70% MCTKD diet to maximize seizure control with gastrointestinal side effects optimally controlled. As long as health care professionals carefully manage MCTKD, many more patients with epilepsy who are not appropriate for CKD or modified Atkins diet or low glycemic index treatment will benefit from this treatment. A comparison between the MCTKD and other KDs is also discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23515148     DOI: 10.4103/2319-4170.107154

Source DB:  PubMed          Journal:  Biomed J        ISSN: 2319-4170            Impact factor:   4.910


  27 in total

1.  Ketogenic diet versus gluten free casein free diet in autistic children: a case-control study.

Authors:  Omnia El-Rashidy; Farida El-Baz; Yasmin El-Gendy; Randa Khalaf; Dina Reda; Khaled Saad
Journal:  Metab Brain Dis       Date:  2017-08-14       Impact factor: 3.584

2.  Increased Hippocampal Afterdischarge Threshold in Ketogenic Diet is Accompanied by Enhanced Kynurenine Pathway Activity.

Authors:  Bartosz Osuch; Karolina Kołosowska; Natalia Chmielewska; Danuta Turzyńska; Alicja Sobolewska; Janusz Szyndler; Piotr Maciejak
Journal:  Neurochem Res       Date:  2022-05-06       Impact factor: 3.996

Review 3.  Potential for Ketotherapies as Amyloid-Regulating Treatment in Individuals at Risk for Alzheimer's Disease.

Authors:  Matthew K Taylor; Debra K Sullivan; Jessica E Keller; Jeffrey M Burns; Russell H Swerdlow
Journal:  Front Neurosci       Date:  2022-06-16       Impact factor: 5.152

Review 4.  Emerging Role of Hepatic Ketogenesis in Fatty Liver Disease.

Authors:  Raja Gopal Reddy Mooli; Sadeesh K Ramakrishnan
Journal:  Front Physiol       Date:  2022-07-04       Impact factor: 4.755

Review 5.  Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet.

Authors:  Michael A Rogawski; Wolfgang Löscher; Jong M Rho
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

6.  The role of metabolic therapy in treating glioblastoma multiforme.

Authors:  Joseph C Maroon; Thomas N Seyfried; Joseph P Donohue; Jeffrey Bost
Journal:  Surg Neurol Int       Date:  2015-04-16

7.  Marked Seizure Reduction after MCT Supplementation.

Authors:  Raed Azzam; Nabil J Azar
Journal:  Case Rep Neurol Med       Date:  2013-12-08

8.  Tolerability and Safety of a Novel Ketogenic Ester, Bis-Hexanoyl (R)-1,3-Butanediol: A Randomized Controlled Trial in Healthy Adults.

Authors:  Oliver Chen; Traci M Blonquist; Eunice Mah; Kristen Sanoshy; Dawn Beckman; Kristin M Nieman; Barbara L Winters; Joshua C Anthony; Eric Verdin; John C Newman; Brianna J Stubbs
Journal:  Nutrients       Date:  2021-06-16       Impact factor: 5.717

9.  Retrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease.

Authors:  Steven Douglas Maynard; Jeff Gelblum
Journal:  Neuropsychiatr Dis Treat       Date:  2013-10-23       Impact factor: 2.570

Review 10.  Potential therapeutic use of the ketogenic diet in autism spectrum disorders.

Authors:  Eleonora Napoli; Nadia Dueñas; Cecilia Giulivi
Journal:  Front Pediatr       Date:  2014-06-30       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.